Fennec Pharmaceuticals (TSE:FRX) Sets New 12-Month High – What’s Next?

Fennec Pharmaceuticals Inc. (TSE:FRX) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as C$11.68 and last traded at C$11.25, with a volume of 300 shares trading hands. The stock had previously closed at C$11.25.

Fennec Pharmaceuticals Price Performance

The business has a 50-day simple moving average of C$8.56 and a two-hundred day simple moving average of C$8.75. The stock has a market capitalization of C$216.95 million, a P/E ratio of -190.57 and a beta of 0.25. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83.

Insiders Place Their Bets

In other news, Director Rostislav Christov Raykov sold 10,000 shares of the firm’s stock in a transaction dated Friday, April 4th. The stock was sold at an average price of C$7.46, for a total transaction of C$74,550.00. Also, Director Jeffrey Hackman bought 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average cost of C$9.77 per share, for a total transaction of C$146,580.00. Over the last quarter, insiders have sold 35,645 shares of company stock valued at $316,021. 16.20% of the stock is currently owned by corporate insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.